○ Common treatment-related adverse events (any grade):○ Fatigue: 27%○ Peripheral sensory neuropathy: 19%○ Pharmacokinetic profile:○ Teliso-V plus nivolumab comparable to Teliso-V monotherapy.○ Antitumor activity:○ Limited overall, with an objective response rate of 7.4%.○ Confirmed partial responses:○ Two patients with PD-L1 positivity and c-Met immunohistochemistry H-score of 190.○ One patient with PD-L1 negativity and c-Met H-score of 290.○ PFS:○ Overall median: 7.2 months.○ Variation among different PD-L1 subgroups (PD-L1+: 7.2 months; PD-L1–: 4.5  months; PD-L1-unknown: not reached). This evidence concerns the gene CD274 and sensory peripheral neuropathy.